To Investigate the Effect of Rosiglitazone and Ramipril on Pre-clinical Vasculopathy in Diabetes and IGT Patients

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim is to examine whether pharmacological interventions with thiazolidinedione and angiotensin converting enzyme (ACE) inhibitors can reverse pre-clinical vasculopathy in newly diagnosed diabetic and IGT individuals.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universiti Sains Malaysia; University of Science Malaysia
• Collaborator: Ministry of Health, Malaysia
• Treatments: Ramipril; Rosiglitazone

Criteria

Inclusion Criteria:

• Newly diagnosed untreated T2DM patients

• Newly diagnosed untreated IGT patients

• Normoglycaemic individuals

• Age: 30-65 years

• Blood Pressure <140/90 mmHg.

Exclusion Criteria:

• Patients with T2DM

• Hypertension (>140/90 mmHg)

• Microvascular and/or macrovascular complications of diabetes

• Severe hyperlipidaemia (>7.8 mmol/L)

• Smokers

• Obese people (BMI>30 Kg/m2)